Ziopharm Oncology Inc (ZIOP) 9.64 $ZIOP
ZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares
GlobeNewswire - Thu Feb 12, 6:36AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 9.64 (-0.35), JPM: 59.67 (+0.10)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 9.64 (-0.35), TROV: 4.99 (-0.17), CRR: 40.35 (+2.73), SLG: 128.59 (-0.65), WMS: 25.03 (+0.36), MLNK: 3.78 (+0.04), RXN: 27.85 (+0.08), KTWO: 19.75 (+0.01), PANW: 135.27 (+2.26), YHOO: 44.42 (+0.50), WHR: 213.23 (+0.18), UA: 73.76 (-0.19), GILD: 101.90 (+1.10), R: 93.92 (+0.41), SIX: 45.11 (-0.05), DATA: 99.90 (+1.40), TW: 131.99 (-0.41), MA: 87.14 (-0.38), NVET: 9.66 (-0.18), IPGP: 87.26 (+0.07)
Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
ZIOPHARM to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 05, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 17 Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 10:30 a.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology prices public offering at USD8.75 per share
M2 - Wed Feb 04, 5:22AM CST
Biotechnology company ZIOPHARM Oncology (NasdaqCM:ZIOP) said on Tuesday that it has priced its public offering of 10,000,000 common stock at USD8.75 per share.
ZIOP: 9.64 (-0.35)
Ziopharm prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:58PM CST
ZIOP: 9.64 (-0.35)
Why Intrexon And Ziopharm Investors Now Face Increased Risk Both Short And Long-Term
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:38PM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
ZIOPHARM Oncology Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 5:32PM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it has priced its previously announced underwritten public offering of common stock consisting of 10,000,000 shares at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from this offering are expected to be approximately $87.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 9.64 (-0.35), JPM: 59.67 (+0.10)
Why Ziopharm Oncology, Inc. Shares Flash-Crashed Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 03, 2:53PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology, Inc . dropped 10%...
ZIOP: 9.64 (-0.35)
Ziopharm down premarket on equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:05AM CST
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology to issue public offering of USD75m common stock
M2 - Tue Feb 03, 4:18AM CST
Biotechnology company ZIOPHARM Oncology (NasdaqCM:ZIOP) said on Monday that it plans to start an underwritten public offering of USD75m of shares of its common stock.
ZIOP: 9.64 (-0.35)
Ziopharm initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:07PM CST
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Feb 02, 3:16PM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to commence an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM.
ZIOP: 9.64 (-0.35), JPM: 59.67 (+0.10)
Today's Dead Cat Bounce Stock Is ZIOPHARM Oncology (ZIOP)
at The Street - Thu Jan 29, 9:18AM CST
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate
ZIOP: 9.64 (-0.35)
Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 9.64 (-0.35), RGDO: 1.17 (+0.02)
Bullish Options Traders Rack Up Quick Wins in Ziopharm Oncology
at The Street - Wed Jan 28, 4:45AM CST
The broader market fell Tuesday, but Ziopharm Oncology was just what the doctor ordered.
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology Announces Exercise of Option to Purchase Additional Shares
GlobeNewswire - Thu Feb 12, 6:36AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 9.64 (-0.35), JPM: 59.67 (+0.10)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 9.64 (-0.35), TROV: 4.99 (-0.17), CRR: 40.35 (+2.73), SLG: 128.59 (-0.65), WMS: 25.03 (+0.36), MLNK: 3.78 (+0.04), RXN: 27.85 (+0.08), KTWO: 19.75 (+0.01), PANW: 135.27 (+2.26), YHOO: 44.42 (+0.50), WHR: 213.23 (+0.18), UA: 73.76 (-0.19), GILD: 101.90 (+1.10), R: 93.92 (+0.41), SIX: 45.11 (-0.05), DATA: 99.90 (+1.40), TW: 131.99 (-0.41), MA: 87.14 (-0.38), NVET: 9.66 (-0.18), IPGP: 87.26 (+0.07)
Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
ZIOPHARM to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 05, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 17 Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 10:30 a.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology prices public offering at USD8.75 per share
M2 - Wed Feb 04, 5:22AM CST
Biotechnology company ZIOPHARM Oncology (NasdaqCM:ZIOP) said on Tuesday that it has priced its public offering of 10,000,000 common stock at USD8.75 per share.
ZIOP: 9.64 (-0.35)
Ziopharm prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:58PM CST
ZIOP: 9.64 (-0.35)
Why Intrexon And Ziopharm Investors Now Face Increased Risk Both Short And Long-Term
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:38PM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
ZIOPHARM Oncology Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 5:32PM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it has priced its previously announced underwritten public offering of common stock consisting of 10,000,000 shares at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from this offering are expected to be approximately $87.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.
ZIOP: 9.64 (-0.35), JPM: 59.67 (+0.10)
Why Ziopharm Oncology, Inc. Shares Flash-Crashed Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 03, 2:53PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Ziopharm Oncology, Inc . dropped 10%...
ZIOP: 9.64 (-0.35)
Ziopharm down premarket on equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:05AM CST
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology to issue public offering of USD75m common stock
M2 - Tue Feb 03, 4:18AM CST
Biotechnology company ZIOPHARM Oncology (NasdaqCM:ZIOP) said on Monday that it plans to start an underwritten public offering of USD75m of shares of its common stock.
ZIOP: 9.64 (-0.35)
Ziopharm initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:07PM CST
ZIOP: 9.64 (-0.35)
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Feb 02, 3:16PM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to commence an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM.
ZIOP: 9.64 (-0.35), JPM: 59.67 (+0.10)
Today's Dead Cat Bounce Stock Is ZIOPHARM Oncology (ZIOP)
at The Street - Thu Jan 29, 9:18AM CST
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate
ZIOP: 9.64 (-0.35)
Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 9.64 (-0.35), RGDO: 1.17 (+0.02)
Bullish Options Traders Rack Up Quick Wins in Ziopharm Oncology
at The Street - Wed Jan 28, 4:45AM CST
The broader market fell Tuesday, but Ziopharm Oncology was just what the doctor ordered.
ZIOP: 9.64 (-0.35)
